We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ChemomAb

News List

Chemomab and AGC Biologics Partner to Manufacture CM-101 for Phase II/III contractpharma
June 25, 2021
AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen to support clinical testing and launch readiness.
Chemomab Receives EU Orphan Drug Designation for Primary Sclerosing Cholangitis Treatment americanpharmaceuticalreview
August 27, 2020
Chemomab announces the European Commission (EC) has granted Orphan Drug Designation (ODD) to its lead drug candidate CM-101 for the treatment of patients with Primary Sclerosing Cholangitis (PSC) ...
ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 americanpharmaceuticalreview
January 11, 2019
ChemomAb announced dosing of the first patient in a Phase 1b repeated dose clinical trial with CM-101 in non-alcoholic fatty liver disease (NAFLD) patients....
ChemomAb Appoints Chairman of the Board americanpharmaceuticalreview
December 05, 2018
ChemomAb announced the appointment of Dr. Stephen Squinto as the company’s chairman of the board.In this role, Dr. Squinto will help guide the company ....